CoChat

Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis

Open access
Richeldi, Luca, Cottin, Vincent, Flaherty, Kevin R., Kolb, Martin, Inoue, Yoshikazu, Raghu, Ganesh, Taniguchi, Hiroyuki, Hansell, David M., Nicholson, Andrew G., Le Maulf, Florence, Stowasser, Susanne, Collard, Harold R. · 2014 · Respiratory Medicine
Cited by 104

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Nintedanib is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF). Data from the Phase II TOMORROW study suggested that nintedanib 150 mg twice daily had clinical benefits with an acceptable safety profile. METHODS: The INPULSIS™ trials are replicate Phase III, randomized, double-blind, studies comparing the efficacy and safety of nintedanib 150 mg twice daily with placebo in patients with IPF. Eligible patients were aged ≥40 years with a diagnosis of IPF within 5 years before randomization who had undergone a chest high-resolution computed tomography (HRCT) scan within 1-year before screening, and who had a forced vital capacity (FVC) of ≥50% predicted and a diffusing capacity for carbon monoxide of 30-79% predicted. Participants were randomized 3:2 to receive nintedanib or placebo for 52 weeks. The primary endpoint is the annual rate of decline in FVC. The key secondary endpoints are change from baseline in the total score on the St. George's Respiratory Questionnaire (a measure of health-related quality of life) over 52 weeks and time to first acute exacerbation. RESULTS: Enrolment of 1066 patients in 24 countries was completed in September 2012. Results will be reported in the first half of 2014. CONCLUSION: The INPULSIS™ trials will determine the efficacy of nintedanib in patients with IPF, including its impact on disease progression as defined by decline in FVC, acute exacerbations and health-related quality of life. In addition, they will characterise the adverse event profile of nintedanib in this patient population. TRIAL REGISTRATION: Registered at ClinicalTrials.gov (identifiers: NCT01335464 and NCT01335477).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.rmed.2014.04.011

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 104

Metadata

Authors
Richeldi, L., Cottin, V., Flaherty, K. R., Kolb, M., Inoue, Y., Raghu, G., Taniguchi, H., Hansell, D. M., Nicholson, A. G., Le Maulf, F., Stowasser, S., & Collard, H. R.
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2014-07
Volume
108
Issue
7
Pages
1023-1030
ISSN
0954-6111 (ISSN-L)
OpenAlex
W1975158384
Cited by
104
References
8
FWCI
9.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1016/j.rmed.2014.04.011
The paper
Richeldi, L., Cottin, V., Flaherty, K. R., Kolb, M., Inoue, Y., Raghu, G., Taniguchi, H., Hansell, D. M., Nicholson, A. G., Le Maulf, F., Stowasser, S., & Collard, H. R. (2014). Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2014.04.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.